Gaebler AJ, Fakour N, Stöhr F, Zweerings J, Taebi A, Suslova M, Dukart J, Hipp JF, Adhikari BM, Kochunov P, Muthukumaraswamy SD, Forsyth A, Eggermann T, Kraft F, Kurth I, Paulzen M, Gründer G, Schneider F, Mathiak K. Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRI. Transl Psychiatry. 2023 13(1):59.
Hart X, Amann F, Brand J, Eichentopf L, Gründer G. Low Escitalopram Concentrations in Patients with Depression predict Treatment Failure: A Naturalistic Retrospective Study. Pharmacopsychiatry. 2023 56(2):73-80.
Hart X, Heesen S, Schmitz CN, Dörfler S, Wedekind D, Gründer G, Hiemke C, Havemann-Reinecke U. Concentrations of escitalopram in blood of patients treated in a naturalistic setting: focus on patients with alcohol and benzodiazepine use disorder. Eur Arch Psychiatry Clin Neurosci. 2023 273(1):75-83. Epub 2022 Oct 7.
Herwig U, Mertens L, Rosal SP, Koller G, Jungaberle A, Borgwardt S, Gründer G. [Psychedelics in Psychiatry - Development and Current State in Germany]. Fortschr Neurol Psychiatr. 2023 91(7-8):311-318. Epub 2023 Jan 4.
Schmidt C, Wolff M, Gründer G, Jungaberle H. [Attitudes of Mental Health Experts Towards Psilocybin]. Fortschr Neurol Psychiatr. 2023 91(3):80-97. Epub 2022 Jun 20.
Wesner K, Hiemke C, Bergemann N, Egberts KM, Fekete S, Gerlach M, Havemann-Reinecke U, Lense XM, Riemer TG, Schoretsanitis G, Uhr M, Zernig G, Gründer G, Hart XM. Therapeutic Reference Range for Olanzapine in Schizophrenia: Systematic Review on Blood Concentrations, Clinical Effects, and Dopamine Receptor Occupancy. J Clin Psychiatry. 2023 84(5)